Current Open Clinical Trials


If you are interested in learning more about the eligibility requirements for any of open studies listed below, please contact the nearest participating University or Christina Mazcko.

To search studies being conducted by other groups please visit Vet Cancer Trials. This will allow you to search by location and tumor type.


COTC021 and COTC022: Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma Compared to Standard of Care


Purpose

All dogs will receive standard of care. Standard of care includes surgical removal of tumor and four doses of carboplatin chemotherapy. Dogs will be randomized at time of enrollment to either be in study COTC022 (standard of care alone) or COTC021 (standard of care followed by 4 months of rapamycin administration). The antimetastatic effects of rapaymcin will be compared to standard of care alone. 160 dogs will be enrolled on this study.

Sponsor: Morris Animal Foundation

Study Numbers: 160 dogs anticipated

Eligibility Requirements

  • Histologically or cytologically confirmed osteosarcoma
  • Measurable disease that is amenable to surgical removal via amputation
  • Favorable performance status
  • Only newly diagnosed dogs are eligible with no prior therapy for osteosarcoma

COTC024: Defining PK and biological activity of systemic oncolytic VSV within a dose/schedule optimization study



Purpose

To define the optimal dose and schedule for an oncolytic virus. Results of this study will be used to inform the design and implementation of clinical trials evaluating VSV-IFNβ-NIS in patients with relapsed or refractory cancer. Dogs will be remain hospitalized for the first 3 days of the study.

Sponsor: Omnis

Study Numbers: 18-20 dogs anticipated


Eligibility Requirements

  • Histologically or cytologically confirmed osteosarcoma
  • Measurable disease that is amenable to surgical removal via amputation
  • Favorable performance status
  • Only newly diagnosed dogs are eligible with no prior therapy for osteosarcoma

Participating Sites: